Psychotropic Medication Prescription for Autism: Data Sources for Decision Making
- 192 Downloads
Currently, there are two medications (i.e., risperidone and aripiprazole) with sufficient established evidence for effectively treating related symptoms (i.e., irritability and hyperactivity) of autism spectrum disorder (ASD). A recent study on the prevalence of psychotropic medication treatment for children with ASD in the USA found that approximately 65% had filled a prescription for at least one psychotropic medication, 35% filled prescriptions across two medication classes, and 15% filled prescriptions across three or more classes concurrently. While these numbers inform rates of psychotropic medication use among this population, little is known about the prescribing practices of practitioners treating ASD symptoms in pediatric populations. There are currently no known empirical studies examining the prescribing practitioner’s perspective and, as a result, it is not known how prescribers are making psychotropic medication management decisions or what factors may influence those decisions. Therefore, the current study sought to evaluate the degree to which prescribers rated the importance of several sources of information when prescribing and managing psychotropic medication for the treatment of core and secondary symptoms of ASD.
KeywordsAutism Pediatric Psychotropic Medication Prescribing
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This research involved human participants, and was approved by the Institutional Review Board at the site at which it was conducted. Informed consent was obtained from all participants.
- American Academy of Child and Adolescent Psychiatry (2012). A Guide for Public Child Serving Agencies on Psychotropic Medications for Children and Adolescents. Retrieved from http://www.aacap.org/App_Themes/AACAP/docs/press/guide_for_community_child_serving_agencies_on_psychotropic_medications_for_children_and_adolescents_2012.pdf. Accessed 26 Feb 2015.
- Barnard-Brak, L., Davis, T. N., Schmidt, M., & Richman, D. M. (2016). Effects associated with on- and off-label stimulant treatment of core autism and ADHD symptoms exhibited by children with autism spectrum disorder. Developmental Neurorehabilitation, 19(1), 46–53 http://dx.doi.org.tcsedsystem.idm.oclc.org/10.3109/17518423.2014.904949.CrossRefGoogle Scholar
- Braüner, J. V., Johansen, L. M., Roesbjerg, T., & Pagsberg, A. K. (2016). Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. Journal of Clinical Psychopharmacology, 36(5), 500–507 http://dx.doi.org.tcsedsystem.idm.oclc.org/10.1097/JCP.0000000000000559.CrossRefGoogle Scholar
- Frazier, T.W., Shattuck, P.T., Carter Narendorf, S., Cooper, B.P., Wagner, M. & Spitznagel, E.L. (2011). Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(6), 571–579.Google Scholar
- George, D., & Mallery, M. (2003). Using SPSS for Windows step by step: a simple guide and reference. Boston, MA: Allyn & Bacon.Google Scholar
- Grove, W. M., & Meehl, P. E. (1996). Comparative efficiency in informal (subjective, impressionistic) and formal (mechanical, algorithmic) prediction procedures: The clinical –statistical controversy. Psychology, Public Policy, and Law, 2(2), 293–323. https://doi.org/10.1037/1076-8918.104.22.1683.CrossRefGoogle Scholar
- Guy, W. (Ed.). (1976). Clinical Global Impressions Scale. Rockville: National Institute of Mental Health.Google Scholar
- Lake, J. A., Denton, D., Lunsky, Y., Shui, A. M., Veenstra-VanderWeele, J., & Anagnostou, E. (2017). Medical conditions and demographic, service, and clinical factors associated with atypical antipsychotic medication use among children with an autism spectrum disorder. Journal of Autism and Developmental Disorders, 47(5), 1391–1402. https://doi.org/10.1007/s10803-017-3058-8.CrossRefGoogle Scholar
- Lopez De-Fede, A., Vyavaharkar, M., & Bellinger, J. D. (2014). Antipsychotic prescriptions for children aged 5 years or younger; do we need policy oversight standards? SAGE Open, 4(4). https://doi.org/10.1177/2158244014555116.
- Lund, A. & Lund, M. (2013). Laerd Statistics Retrieved from https://statistics.laerd.com/aboutus.php.
- Madden, J. M., Lakoma, M. D., Lynch, F. L., Rusinak, D., Owen-Smith, A. A., Coleman, K. J., Quinn, V. P., Yau, V. M., Qian, Y. X., & Croen, L. A. (2017). Psychotropic medication use among insured children with autism spectrum disorder. Journal of Autism and Developmental Disorders, 47(1), 144–154. https://doi.org/10.1007/s10803-016-2946-7.CrossRefGoogle Scholar
- Murray, M. L., Hsia, Y., Glaser, K., Simonoff, E., Murphy, D. G., Asherson, P. J., Eklund, H., & Wong, I. C. J. (2014). Pharmacological treatments prescribed to people with autism spectrum disorder in primary health care. Psychopharmacology, 231(6), 1011–1021 http://dx.doi.org.tcsedsystem.idm.oclc.org/10.1007/s00213-013-3140-7.CrossRefGoogle Scholar
- Myers, S. M. (2008). Psychopharmacologic approaches to challenging behaviors in individuals with autism. In B. K. Shapiro & P. J. Accardo (Eds.), Autism frontiers: Clinical issues and innovations (pp. 153–175). Baltimore: P. H. Brookes.Google Scholar
- Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., et al. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry, 55(6), 456–468 http://dx.doi.org.tcsedsystem.idm.oclc.org/10.1016/j.jaac.2016.03.012.CrossRefGoogle Scholar
- Paul, A. R., Mckechanie, A. G., Johnstone, E. C., Cunningham Owens, D. G., & Stanfield, A. C. (2015). Brief report: The association of autistic traits and behavioral patterns in adolescents receiving special educational assistance. Journal of Autism and Developmental Disorders, 45(9), 3055–3060 http://dx.doi.org.tcsedsystem.idm.oclc.org/10.1007/s10803-015-2445-2.CrossRefGoogle Scholar
- Poling, A. D., Ehrhardt, K., & Li, A. (2017). Pharmacotherapy. In J. L. Matson (Ed.), Handbook of treatments for autism (pp. 459476). New York: Springer.Google Scholar
- Rivard, M., Forget, J., Giroux, N., Mello, C., Kerr, K., & Regli, G. (2016). Observation of socially appropriate and inappropriate behaviors among children with autism spectrum disorder during an early behavioral intervention program. Journal on Developmental Disabilities, 22(1), 52–67 Retrieved from https://tcsedsystem.idm.oclc.org/login?url=http://search.proquest.com.tcsedsystem.idm.oclc.org/docview/1823375716?accountid=34120.Google Scholar
- Rosenberg, R., Mandell, D. S., Farmer, J. E., Kiely Law, J., Marvin, A. R., & Law, P. A. (2010). Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorders, 40(3), 342–351. https://doi.org/10.1007/s10803-009-0878-1.CrossRefGoogle Scholar
- Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children’s Yale-Brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child & Adolescent Psychiatry, 36(6), 844–852. https://doi.org/10.1097/00004583-199706000-00023.CrossRefGoogle Scholar
- Zonfrillo, M. R., Penn, J. V., & Leonard, H. L. (2005). Pediatric psychotropic polypharmacy. Psychiatry, 2(8), 14–19.Google Scholar